A Single Center Retrospective Study Analysing Incidence and Risk Factors Associated with Bleeding Events in Patients Receiving Acalabrutinib Therapy
Latest Information Update: 29 Jan 2022
At a glance
- Drugs Acalabrutinib (Primary)
- Indications Chronic lymphocytic leukaemia; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions
Most Recent Events
- 29 Jan 2022 New trial record
- 14 Dec 2021 Results presented at the 63rd American Society of Hematology Annual Meeting and Exposition